Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Medical cannabis vouchers may cut opioid use in chronic pain patients

NCT ID NCT04495725

Disease control Sponsor: Vireo Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving adults with chronic pain discounted vouchers for medical cannabis soft-gel capsules could help them reduce their opioid painkiller use. 270 participants were randomly assigned to receive vouchers for placebo or cannabis capsules with different THC-to-CBD ratios. The main goal was to see if the vouchers led to lower total opioid doses over the study period.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
medical cannabis soft-gel capsules (various THC:CBD ratios)
What this could lead to
If successful, this could show that providing discounted medical cannabis helps people with chronic pain lower their opioid use, potentially reducing opioid-related harms.
What could go wrong
This is a completed trial with 270 participants, but results may not apply to all pain types or cannabis products. The use of vouchers may not reflect real-world access or long-term effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

270 people

The number who actually took part.

Started

Oct 2020

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. \>18 years old 2. English or Spanish fluency 3. active certification for medical cannabis 4. intends to have a soft-gel capsule product dispensed at Vireo Health 5. medical cannabis qualifying conditions or complications of (a) chronic pain, or (b) pain that degrades health and functional capability as an alternative to opioid use or substance use disorder or (c) severe or chronic pain 6. joint or neuropathic pain 7. current severe pain 8. dispensed opioids analgesics within the last 60 days To maintain the integrity of the study, we do not disclose all inclusion criteria to potential participants. Exclusion Criteria: 1. inability to provide informed consent 2. inability to complete study visits over 14 weeks 3. terminal illness 4. current or prior psychotic disorder 5. current or prior buprenorphine or methadone treatment for opioid use disorder 6. NYS medical marijuana prescriber does not approve changes to product and dosing recommendations listed on the participant's certification form 7. Allergy to tapioca or coconut 8. currently pregnant, planning to become pregnant within the next 3 months, or breastfeeding 9. a condition that is considered by a pharmacist or medical provider to be a clinical contraindication to medical cannabis use (e.g. unstable cardiac arrhythmia or specific drug-drug interaction)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cannabis dependence Chronic Pain chronic pain syndrome opioid abuse Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pain Marijuana Opioid use

Contacts and locations

Locations

  • Vireo Health of New York

    Queens, New York, 11373, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.